Brought to you by 
Dako designs test to predict benefit of ImClone drug
09 Oct 2020
Executive Summary
Dako Corp. (cancer diagnostics) will develop an epidermal growth factor receptor (EGFr) screening kit that will used to identify those tumors that may benefit from treatment with ImClone Systems' IMC-C225, a monoclonal antibody designed to target and block EGFr.
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Large Molecule
- Pharmacogenetics-Pharmacogenomics
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Dako designs test to predict benefit of ImClone drug
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice